Treatment with the Src inhibitor, PP2, was reported to significantly reduce fibroblast migration stimulated by platelet-derived growth factor-BB (PDGF-BB) and to reduce lung fibrosis in mice in vivo [58]. The gene discussed is SRC; the disease is pulmonary fibrosis.